Hofman, Michael S., Emmett, Louise, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Weickhardt, Andrew, Scott, Andrew M., Lee, Sze-Ting, Kwan, Edmond M., Azad, Arun A., Ramdave, Shakher, Redfern, Andrew D., Sandhu, Shahneen, Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Y., McJannett, Margaret M., Stockler, Martin R., Violet, John A., Williams, Scott G., Iravani, Amir, Martin, Andrew J., Davis, Ian D., , Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Ng, Siobhan. The Lancet Publishing Group; 2021. [Lu-177]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.

Hofman, Michael S., Emmett, Louise, Ng, Siobhan, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Weickhardt, Andrew, Scott, Andrew M., Lee, Sze-Ting, Kwan, Edmond M., Azad, Arun A., Ramdave, Shakher, Sandhu, Shahneen, Redfern, AD, Macdonald, W, Guminski, A, Hsiao, E, Chua, W, Lin, P, Zhang, AY, Stockler, MR, Williams, SG, Martin, AJ, Iravani, Amir, Davis, ID, TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group,, Buteau, James P., Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D.. Lancet Publishing Group; 2024. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.